alpha-(3-methoxybenzenethiomethyl)acrylic acid | 116856-57-6

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯酚醚
• 英文名称: alpha-(3-methoxybenzenethiomethyl)acrylic acid
• 英文别名: 2-[(3-Methoxyphenyl)sulfanylmethyl]prop-2-enoic acid
• CAS: 116856-57-6
• 化学式: C₁₁H₁₂O₃S
• 分子量: 224.28
• InChiKey: LHQOFPWCSXXNCH-UHFFFAOYSA-N

物化性质

• 沸点：
  388.1±37.0 °C(Predicted)
• 密度：
  1.23±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.4
• 重原子数：
  15
• 可旋转键数：
  5
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.18
• 拓扑面积：
  71.8
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  alpha-(3-methoxybenzenethiomethyl)acrylic acid 生成 3,4-dihydro-5-methoxy-2H-[1]-benzothiopyran-3-carboxylic acid
  参考文献：
  名称：

  HUTCHISON, ALAN J.

  摘要：

  DOI：
• 作为产物：
  描述：

  3-甲氧基苯硫酚 、 2-(溴甲基)丙烯酸 在 氢氧化钾 作用下， 以 二甲基亚砜 为溶剂， 生成 alpha-(3-methoxybenzenethiomethyl)acrylic acid
  参考文献：
  名称：

  2-(substituted amino) adenosines as antihypertensives

  摘要：

  本文披露了公式##STR1##中的2-取代腺苷衍生物，其中R代表定义如下的取代氨基团##STR2##；其药学上可接受的酯衍生物，其中游离羟基以药学上可接受的前药酯的形式酯化；以及其药学上可接受的盐；包括所述化合物的药物组合物；其制备方法；及其在哺乳动物中作为治疗有效的腺苷-2（A-2）激动剂的用途。

  公开号：

  US05034381A1

文献信息

• N.sub.9 -cyclopentyl-substituted adenine derivatives having adenosine-2
  申请人：Ciba-Geigy Corporation

  公开号：US04954504A1

  公开（公告）日：1990-09-04

  The compound of the formula I ##STR1## wherein R, R.sub.3 and R.sub.5 independently represent hydrogen or hydroxy provided that at least one of R, R.sub.3 and R.sub.5 represents hydroxy; R.sub.1 represents hydrogen, lower alkyl, C.sub.3 -C.sub.7 -alkenyl, hydroxy-lower alkyl, optionally substituted cycloalkyl or optionally substituted cycloalkyl-lower alkyl, bicycloalkyl, bicycloalkyl-lower alkyl, adamantyl, tetrahydropyranyl, tetrahydrothiopyranyl, tetrahydropyranyl-lower alkyl, tetrahydrothiopyranyl-lower alkyl, adamantyl-lower alkyl, aryl-hydroxy-lower alkyl, aryl, aryl-lower alkyl, aryl-C.sub.3 -C.sub.6 -cycloalkyl, 9-fluorenyl, 9-fluorenyl-lower alkyl or cycloalkenyl-lower alkyl; or R.sub.1 represents a bicyclic benzo-fused 5 or 6-membered saturated cyabocyclic radical or a benzo-fused 5 or 6-membered saturated heterocyclic radical containing a heteroatom selected from oxygen and sulfur directly attached to the fused benzene ring, any said bicyclic radicals being optionally substituted on the benzo portion by lower alkyl, lower alkoxy or halogen, or R.sub.1 represents any said bicyclic radical substituted-lower alkyl; R.sub.2 represents hydrogen, halogen, --S--R.sub.1 ', --NR.sub.b --R.sub.1 ', or --NH--R.sub.1 ' in each of which R.sub.1 ' has meaning as defined for R.sub.1 provided that R.sub.1 ' in --SR.sub.1 ' does not represent hydrogen; R.sub.b represents lower alkyl; R.sub.4 represents hydroxymethyl provided that R.sub.2 does not represent either hydrogen or --NHR.sub.1 ' in which R.sub.1 ' represents either hydrogen or lower alkyl; or R.sub.4 represents lower alkoxymethyl or lower alkylthiomethyl; or R.sub.4 represents --CONHR.sub.6 in which R.sub.6 represents lower alkyl; aryl-lower alkyl, C.sub.3 -C.sub.6 -cycloalkyl or hydroxy-lower alkyl; pharmaceutically acceptable ester derivatives thereof in which free hydroxy groups are esterified in form of a pharmaceutically acceptable ester; and pharmaceutically acceptable salts thereof; methods for their preparation; and their use as adenosine receptor agonists are disclosed.

  公式I的化合物如下：其中R、R.sub.3和R.sub.5独立地表示氢或羟基，但至少其中一个表示羟基；R.sub.1表示氢、较低的烷基、C.sub.3-C.sub.7-烯基、羟基-较低的烷基、可选地取代的环烷基或可选地取代的环烷基-较低的烷基、双环烷基、双环烷基-较低的烷基、金刚烷基、四氢吡喃基、四氢硫吡喃基、四氢吡喃基-较低的烷基、四氢硫吡喃基-较低的烷基、金刚烷基-较低的烷基、芳基-羟基-较低的烷基、芳基、芳基-较低的烷基、芳基-C.sub.3-C.sub.6-环烷基、9-芴基、9-芴基-较低的烷基或环烯基-较低的烷基；或R.sub.1表示一个双环苯并5或6-成员饱和环的腈状环基或一个苯并5或6-成员饱和杂环基，其中所述杂原子从氧和硫直接连接到融合苯环，任何所述双环基在苯部分上可选地被较低的烷基、较低的烷氧基或卤素取代，或R.sub.1表示任何所述双环基取代的较低烷基；R.sub.2表示氢、卤素、--S--R.sub.1 '、--NR.sub.b--R.sub.1 '或--NH--R.sub.1'，其中在每个中R.sub.1'的含义如R.sub.1所定义，但在--SR.sub.1'中，R.sub.1'不表示氢；R.sub.b表示较低的烷基；R.sub.4表示羟甲基，但当R.sub.2不表示氢或--NHR.sub.1'时，其中R.sub.1'表示氢或较低的烷基；或R.sub.4表示较低的烷氧甲基或较低的烷硫甲基；或R.sub.4表示--CONHR.sub.6，其中R.sub.6表示芳基-较低的烷基、C.sub.3-C.sub.6-环烷基或羟基-较低的烷基；还公开了其药学上可接受的酯衍生物，其中游离羟基以药学上可接受的酯形式酯化，以及其药学上可接受的盐；公开了其制备方法；以及其作为腺苷受体激动剂的用途。
• N9-cyclopentyl-substituted adenine derivatives
  申请人：CIBA-GEIGY AG

  公开号：EP0267878A1

  公开（公告）日：1988-05-18

  The compounds of the formula I wherein R, R3 and R5 independently represent hydrogen or hydroxy provided that at least one of R, R3 and R5 represents hydroxy; R1 represents hydrogen, lower alkyl, C3-C7alkenyl, hydroxy-lower alkyl, C3-C6cycloalkyl, C3-C6cycloalkyl-lower alkyl, 2-norbornyl, 2-norbornyl-lower alkyl, aryl, aryl-lower alkyl, aryl-C3-C6cycloalkyl, 9-fluorenyl or 9-fluorenyl-lower alkyl; or R1 represents a bicyclic benzo-fused 5 or 6-membered saturated carbocyclic radical or a benzo fused 5 or 6-membered saturated heterocyclic radical containing a heteroatom selected from oxygen and sulfur directly attached to the fused benzene ring, any said bicyclic radicals being optionally substituted on the benzo portion by lower alkyl, lower alkoxy or halogen; R2 represents hydrogen, halogen, -SR1 or -N(R9)R1 in each of which R1 has meaning as defined hereinbefore provided that R1 in -SR1 does not represent hydrogen; R9 represents hydrogen or lower alkyl; R4 represents hydroxymethyl provided that R2 does not represent either hydrogen or -NHRI in which R1 represents either hydrogen or lower alkyl; or R4 represents lower alkoxymethyl, lower alkylthiomethyl or -CONHR6 in which R6 represents lower alkyl, aryl-lower alkyl, C3-Cscycloalkyl or hydroxy-lower alkyl; pharmaceutically acceptable ester derivatives thereof in which free hydroxy groups are esterified in form of a pharmaceutically acceptable ester; and salts thereof; methods for their preparation; and their use as adenosine receptor agonists are disclosed.

  式 I 的化合物 其中R、R3和R5独立地代表氢或羟基，但R、R3和R5中至少有一个代表羟基；R1代表氢、低级烷基、C3-C7烯基、羟基-低级烷基、C3-C6环烷基、C3-C6环烷基-低级烷基、2-降冰片基、2-降冰片基-低级烷基、芳基、芳基-低级烷基、芳基-C3-C6环烷基、9-芴基或9-芴基-低级烷基；或 R1 代表双环苯并 5 或 6 元饱和碳环基，或苯并 5 或 6 元饱和杂环基，其中含有一个选自氧和硫的杂原子，直接连接到苯并环上，任何上述双环基的苯并部分可选择被低级烷基、低级烷氧基或卤素取代；R2 代表氢、卤素、-SR1 或-N(R9)R1，其中每个 R1 的含义如前文所定义，条件是 -SR1 中的 R1 不代表氢；R9 代表氢或低级烷基；R4 代表羟甲基，条件是 R2 不代表氢或-NHRI，其中 R1 代表氢或低级烷基；或R4代表低级烷氧基甲基、低级烷硫基甲基或-CONHR6，其中R6代表低级烷基、芳基-低级烷基、C3-Cscycloalkyl或羟基-低级烷基；公开了其药学上可接受的酯衍生物，其中游离羟基以药学上可接受的酯的形式酯化；及其盐；其制备方法；及其作为腺苷受体激动剂的用途。
• Certain adenosine 5'-carboxamide derivatives
  申请人：CIBA-GEIGY AG

  公开号：EP0277917A2

  公开（公告）日：1988-08-10

  The compounds of the formula I wherein R represents hydrogen or lower alkyl; R¹ represents cyclo­alkyl, cycloalkyl-lower alkyl, 2-norbornanyl, 2-norbornanyl-lower alkyl, aryl, aryl-lower alkyl, aryl-cycloalkyl, 9-fluorenyl, diaryl-lower alkyl or 9-fluorenyl-lower alkyl; or R¹ represents a bicyclic benzo-fused 5- or 6-membered saturated carbocyclic radical or a benzo-fused 5- or 6-membered saturated heterocyclic radical containing a heteroatom selected from oxygen and sulfur which is directly attached to the fused benzene ring, any said bicyclic radical being unsubstituted or substituted on the benzo portion by lower alkyl, lower alkoxy, hydroxy, halogen or trifluoromethyl, or by a substituent -W-Z in which W represents a direct bond, lower alkylene, lower alkenylene, thio-lower alkylene or oxy-lowe alkylene and Z represents cyano, carboxy or carboxy derivatized in the form of a pharmaceutically acceptable ester or amide; R² represents hydrogen, lower alkyl or aryl-lower alkyl; R³ represents hydrogen or hydroxy; R⁴ represents hydrogen, lower alkyl, aryl-lower alkyl, cycloalkyl or hydroxy-lower alkyl; pharmaceutically accept­able ester derivatives thereof in which free hydroxy groups are esterified in form of a pharmaceutically acceptable ester; pharmaceutically acceptable salts thereof; their preparation, and their use as adenosine-2 receptor agonists are disclosed.

  式 I 的化合物 其中 R 代表氢或低级烷基；R¹ 代表环烷基、环烷基-低级烷基、2-降冰片烷基、2-降冰片烷基-低级烷基、芳基、芳基-低级烷基、芳基-环烷基、9-芴基、二芳基-低级烷基或 9-芴基-低级烷基；或 R¹ 代表双环苯并融合的 5 或 6 元饱和碳环基，或苯并融合的 5 或 6 元饱和杂环基，其中含有直接连接到融合苯环上的选自氧和硫的杂原子，任何上述双环基均未被取代或在苯并部分被低级烷基取代、低级烷氧基、羟基、卤素或三氟甲基，或取代基-W-Z，其中 W 代表直接键、低级亚烷基、低级亚烯基、硫代低级亚烷基或氧代低级亚烷基，Z 代表氰基、羧基或以药学上可接受的酯或酰胺形式衍生的羧基；R²代表氢、低级烷基或芳基-低级烷基；R³代表氢或羟基；R⁴代表氢、低级烷基、芳基-低级烷基、环烷基或羟基-低级烷基；公开了其药学上可接受的酯衍生物，其中游离羟基以药学上可接受的酯的形式酯化；其药学上可接受的盐；其制备及其作为腺苷-2 受体激动剂的用途。
• US4801605A
  申请人：——

  公开号：US4801605A

  公开（公告）日：1989-01-31
• US4992465A
  申请人：——

  公开号：US4992465A

  公开（公告）日：1991-02-12